MBX Biosciences (MBX) said Friday that Chief Financial Officer Richard Bartram will step down, effective March 15, and that John Smither has been named interim CFO.
The company said in a regulatory filing that Bartram will serve as a consultant to the company following his resignation and that it has begun a search for a new CFO.
MBX said Bartram's departure is not related to any disagreement with the company or its auditors.
Shares of MBX Biosciences were 1.3% lower in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.